| 95.35 -4.56 (-4.56%) | 07-16 16:00 | |||||||||||||
|
|
| Short term |   |
|||
| Mid term |  |
|||
| Targets | 6-month : | 119.56 | 1-year : | 139.65 |
| Resists | First : | 102.37 | Second : | 119.56 |
| Pivot price | 96.3  |
|||
| Supports | First : | 81.65 | Second : | 68.84 |
| MAs | MA(5) : | 98.55 |
MA(20) : | 93.73 |
| MA(100) : | 84.12 |
MA(250) : | 55.58 |
|
| MACD | MACD : | 3.3 |
Signal : | 3.1 |
| %K %D | K(14,3) : | 76.8 |
D(3) : | 82.3 |
| RSI | RSI(14): 53.7 |
|||
| 52-week | High : | 102.37 | Low : | 18.07 |
Price has closed below its short-term moving average. Short-term moving average is currently above mid-term; and above long-term moving average. From the relationship between price and moving averages: This stock is NEUTRAL in short-term; and BULLISH in mid-long term.[ DNTH ] has closed above bottom band by 42.1%. Bollinger Bands are 31.3% narrower than normal. The current width of the bands does not suggest anything about the future direction or movement of prices.
| If tomorrow: | Open lower | Open higher |
| High: | 99.8 - 100.47 | 100.47 - 101.02 |
| Low: | 92.38 - 93.01 | 93.01 - 93.53 |
| Close: | 94.42 - 95.45 | 95.45 - 96.31 |
Dianthus Therapeutics, Inc., a clinical-stage biotechnology company, engages in the development of therapies for patients with severe autoimmune diseases. Its lead clinical-stage candidate, claseprubart, a monoclonal antibody engineered with extended half-life, improved potency, and high selectivity for only the active C1s complement protein; and DNTH212, a bifunctional fusion protein that targets plasmacytoid dendritic cell (pDC) BDCA2 to reduce Type 1 interferon production, while simultaneously inhibiting BAFF/APRIL to suppress B cell function. Dianthus Therapeutics, Inc. was founded in 2019 and is headquartered in New York, New York.
Mon, 13 Jul 2026
[Form 4] Dianthus Therapeutics, Inc. /DE/ Insider Trading Activity - Stock Titan
Thu, 09 Jul 2026
Dianthus Therapeutics (DNTH) Starts Phase 3 EMERGE Trial, Is The Upside Already Priced In? - simplywall.st
Thu, 09 Jul 2026
[144] Dianthus Therapeutics, Inc. /DE/ SEC Filing - Stock Titan
Sun, 05 Jul 2026
Enterprise value to revenue forward of Dianthus Therapeutics, Inc. – NASDAQ:DNTH - TradingView
Thu, 18 Jun 2026
Dianthus (DNTH) SVP uses 10b5-1 plan to sell 30,000 shares - Stock Titan
Wed, 10 Jun 2026
Dianthus drops as Sanofi halts trial for peer drug (DNTH) - Seeking Alpha
| Price to Book Value: P/BV, a ratio used to compare book value to its current market price, to gauge whether a stock is valued properly. |
Underperform |
| Price to Earnings: PE, the ratio for valuing a company that measures its current share price relative to its earnings per share (EPS). |
Underperform |
| Discounted cash flow: DCF, a valuation method used to estimate the value of an investment based on its expected future cash flows. |
Underperform |
| Return on Assets: ROA, indicates how profitable a company is in relation to its total assets, how efficiently uses assets to generate a profit. |
Underperform |
| Return on Equity: ROE, a measure of financial performance calculated by dividing net income by equity. a gauge of profitability and efficiency. |
Underperform |
| Debt to Equity: evaluate financial leverage, reflects the ability of equity to cover outstanding debts in the event of a business downturn. |
Outperform |
|
Exchange:
NASDAQ
|
|
|
Sector:
Healthcare
|
|
|
Industry:
Biotechnology
|
|
| Shares Out | 0 (M) |
| Shares Float | 55 (M) |
| Held by Insiders | 5.46e+007 (%) |
| Held by Institutions | 0.1 (%) |
| Shares Short | 6,690 (K) |
| Shares Short P.Month | 0 (K) |
| EPS | -1.9117e+008 |
| EPS Est Next Qtrly | 0 |
| EPS Est This Year | 0 |
| EPS Est Next Year | 0 |
| Book Value (p.s.) | 0 |
| Profit Margin | 0 % |
| Operating Margin | -10 % |
| Return on Assets (ttm) | 50.3 % |
| Return on Equity (ttm) | -15 % |
| Qtrly Rev. Growth | 1.34e+006 % |
| Gross Profit (p.s.) | -668.89 |
| Sales Per Share | -252.23 |
| EBITDA (p.s.) | 1.48889e+007 |
| Qtrly Earnings Growth | -4.2 % |
| Operating Cash Flow | 0 (M) |
| Levered Free Cash Flow | -130 (M) |
| PE Ratio | -0.01 |
| PEG Ratio | 0 |
| Price to Book value | 0 |
| Price to Sales | -0.38 |
| Price to Cash Flow | 0.38 |
| Dividend | 0 |
| Forward Dividend | 9.53e+006 |
| Dividend Yield | 0% |
| Dividend Pay Date | Invalid DateTime. |
| Ex-Dividend Date | Invalid DateTime. |
|
|
|
|
|
|
|
|
|